Scottsmyname, I will only clarify that IMO there will not be any phase 3 in Multiple system atrophy because MSA is an orphan disease and ATH434 has been granted an orphan status in the USA and EU. With orphan status, a drug can get to the market after positive results in phase 2. IMO, when Stamler has been talking about phase 3, he is talking about a phase 3 study for PD, even though he has not directly told so. It would be stupid to do a phase 3 study on MSA patients but very clever after the successful ape study to do a phase 3 study on PD patients. But of course, the side effects in phase 2 need to be close to the same level as in the placebo group.
Scottsmyname, I will only clarify that IMO there will not be any...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $26.81K | 4.868M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 42771258 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 20563308 | 22 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.6¢ | 0.5¢ | 1735805 | ||
| Last updated 13.27pm 15/05/2024 ? | |||||
| ATH (ASX) Chart |